Thea Pharma patents expiration
1. Akten patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759401 | THEA PHARMA | Aqueous gel formulation and method for inducing topical anesthesia |
Jul, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 07, 2011 |
Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 October, 2008
Treatment: Method of inducing topical anesthesia in the eye
Dosage: GEL;OPHTHALMIC
AKTEN family patents
2. Azasite patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6159458 | THEA PHARMA | Sustained release ophthalmic compositions containing water soluble medicaments |
Nov, 2017
(6 years ago) | |
| US6861411 | THEA PHARMA | Method of treating eye infections with azithromycin |
Nov, 2018
(5 years ago) | |
| US7056893 | THEA PHARMA | Topical treatment for prevention of ocular infections |
Mar, 2019
(5 years ago) | |
| US6239113 | THEA PHARMA | Topical treatment or prevention of ocular infections |
Mar, 2019
(5 years ago) | |
| US6569443 | THEA PHARMA | Topical treatment or prevention of ocular infections |
Mar, 2019
(5 years ago) | |
Drugs and Companies using AZITHROMYCIN ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Method of combating bacteria in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
AZASITE family patents
3. Iyuzeh patents
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637054 | THEA PHARMA | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives |
Jul, 2031
(7 years from now) | |
Drugs and Companies using LATANOPROST ingredient
Market Authorisation Date: 13 December, 2022
Treatment: Topical treatment of ocular hypertension and glaucoma
Dosage: SOLUTION/DROPS;OPHTHALMIC
IYUZEH family patents
4. Zioptan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5886035 | THEA PHARMA | Difluoroprostaglandin derivatives and their use |
Dec, 2017
(6 years ago) | |
| US10864159 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(5 years from now) | |
| US9999593 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 10, 2017 |
Drugs and Companies using TAFLUPROST ingredient
NCE-1 date: 11 February, 2016
Market Authorisation Date: 10 February, 2012
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZIOPTAN family patents